EQUILIN

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C18H20O2
Molecular Weight	268.3502
Optical Activity	UNSPECIFIED
Defined Stereocenters	3 / 3
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

[H][C@@]12CCC(=O)[C@@]1(C)CC[C@@]3([H])C2=CCC4=C3C=CC(O)=C4

InChI

InChIKey=WKRLQDKEXYKHJB-HFTRVMKXSA-N

InChI=1S/C18H20O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3-5,10,14,16,19H,2,6-9H2,1H3/t14-,16+,18+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C18H20O2
Molecular Weight	268.3502
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	3 / 3
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9927655

Equilin is one of the active components of estrogens used in estrogen replacement therapy. This compound is used as a sulfate conjugate in drug Premarin. Equili is an inhibitor of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1), a key enzyme responsible for elevated levels of 17beta-estradiol (E2) in breast tumor tissues. Thus equilin reduce the E2 levels in breast tissues and hence the reduce risk of estrogen-dependent breast cancer.

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Estradiol 17-beta-dehydrogenase 1 1 Target ID: P14061 Gene ID: 3292.0 Gene Symbol: HSD17B1 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/9927655	Inhibitor 8297

Conditions

Condition	Modality	Targets	Highest Phase	Product
Unknown 2578

PubMed

Title	Date	PubMed
Structure of the ternary complex of human 17beta-hydroxysteroid dehydrogenase type 1 with 3-hydroxyestra-1,3,5,7-tetraen-17-one (equilin) and NADP+.	1999 Feb 2	9927655
Synthesis of ring B unsaturated estriols. Confirming the structure of a diagnostic analyte for Smith-Lemli-Opitz syndrome.	2001 Aug 9	11483057
Evidence that a metabolite of equine estrogens, 4-hydroxyequilenin, induces cellular transformation in vitro.	2001 Jan	11170511
Synthesis and reactivity of the catechol metabolites from the equine estrogen, 8,9-dehydroestrone.	2001 Jun	11409947
Equine estrogens induce apolipoprotein E and glial fibrillary acidic protein in mixed glial cultures.	2002 May 3	11959417
Investigations into the biosynthetic pathways for classical and ring B-unsaturated oestrogens in equine placental preparations and allantochorionic tissues.	2002 Nov	12589948
Equine estrogens differentially inhibit DNA fragmentation induced by glutamate in neuronal cells by modulation of regulatory proteins involved in programmed cell death.	2003 Dec 23	14693041
Mixtures of estrogenic contaminants in bile of fish exposed to wastewater treatment works effluents.	2005 Apr 15	15884336
Separation and detection of the isomeric equine conjugated estrogens, equilin sulfate and delta8,9-dehydroestrone sulfate, by liquid chromatography--electrospray-mass spectrometry using carbon-coated zirconia and porous graphitic carbon stationary phases.	2005 Aug 12	16078686
Select estrogens within the complex formulation of conjugated equine estrogens (Premarin) are protective against neurodegenerative insults: implications for a composition of estrogen therapy to promote neuronal function and prevent Alzheimer's disease.	2006 Mar 13	16533397
Mechanism of translesion synthesis past an equine estrogen-DNA adduct by Y-family DNA polymerases.	2007 Aug 31	17603077
Effects of estrogens and selective estrogen receptor modulators on vascular reactivity in the perfused mesenteric vascular bed.	2007 Nov	17881618
Structure activity relationships and differential interactions and functional activity of various equine estrogens mediated via estrogen receptors (ERs) ERalpha and ERbeta.	2008 Oct	18599548
Determination of absolute configurations of 4-hydroxyequilenin-cytosine and -adenine adducts by optical rotatory dispersion, electronic circular dichroism, density functional theory calculations, and mass spectrometry.	2008 Sep	18680315
Determination of endocrine disrupting compounds using temperature-dependent inclusion chromatography: I. Optimization of separation protocol.	2009 Oct 30	19362314
Pharmacokinetics of a modified-release estrogen tablet.	2010 Sep-Oct	21043366
Synthesis and biological evaluation of (6- and 7-phenyl) coumarin derivatives as selective nonsteroidal inhibitors of 17β-hydroxysteroid dehydrogenase type 1.	2011 Jan 13	21138273
FDA-approved drugs and other compounds tested as inhibitors of human glutathione transferase P1-1.	2013 Sep 5	23769903
Differing species responsiveness of estrogenic contaminants in fish is conferred by the ligand binding domain of the estrogen receptor.	2014 May 6	24689804

Patents

Sample Use Guides

In Vivo Use Guide

Unknown

Route of Administration: Unknown

In Vitro Use Guide

Unknown

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:47:13 GMT 2023` Edited by `admin` on `Fri Dec 15 16:47:13 GMT 2023`
Record UNII	08O86EX0J4
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

EQUILIN

Common Name

English

EQUILIN [USP-RS]

Common Name

English

NSC-10971

Code

English

EQUILIN [MI]

Common Name

English

EQUILIN [USP MONOGRAPH]

Common Name

English

EQUILIN [MART.]

Common Name

English

3-Hydroxyestra-1,3,5(10),7-tetraen-17-one

Systematic Name

English

Equilin [WHO-DD]

Common Name

English

ESTRA-1,3,5(10),7-TETRAEN-17-ONE, 3-HYDROXY-

Systematic Name

English

Classification Tree Code System Code

NCI_THESAURUS

C2293